Affordable Access

Access to the full text

Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story

Authors
  • Efimov, G. A.1, 2, 3
  • Raats, J. M. H.4
  • Chirivi, R. G. S.4
  • van Rosmalen, J. W. G.4
  • Nedospasov, S. A.2, 3, 5
  • 1 Ministry of Healthcare of the Russian Federation, National Research Center for Hematology, Moscow, 125167, Russia , Moscow (Russia)
  • 2 Russian Academy of Sciences, Engelhardt Institute of Molecular Biology, Moscow, 11991, Russia , Moscow (Russia)
  • 3 Moscow State University, Moscow, 119991, Russia , Moscow (Russia)
  • 4 ModiQuest B.V., AE Oss, 5349, The Netherlands , AE Oss (Netherlands)
  • 5 Lobachevsky University of Nizhny Novgorod, Nizhny Novgorod, 603022, Russia , Nizhny Novgorod (Russia)
Type
Published Article
Journal
Molecular Biology
Publisher
Pleiades Publishing
Publication Date
Nov 01, 2017
Volume
51
Issue
6
Pages
921–926
Identifiers
DOI: 10.1134/S0026893317060061
Source
Springer Nature
Keywords
License
Yellow

Abstract

Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal antibodies. Currently, anti-TNF therapy is used by millions of patients worldwide. At the moment, fully human anti-TNF antibody Adalimumab is the best-selling anti-cytokine drug in the world. Here, we present a story about a highly potent anti-TNF monoclonal antibody initially characterized more than 20 years ago and further developed into chimeric and humanized versions. We present comparative analysis of this antibody with Infliximab and Adalimumab.

Report this publication

Statistics

Seen <100 times